전이성 유방암 치료 시장 : 기회 및 전략(-2035년)

Metastatic breast cancer treatment refers to the medical treatment of breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body, such as the bones, liver, lungs, or brain (also known as stage IV breast cancer). The primary purpose of metastatic breast cancer treatment is to control disease progression, relieve symptoms, and extend survival while maintaining quality of life.

The metastatic breast cancer treatment market consists of sales, by entities (organizations, sole traders, or partnerships), of treatments that are primarily used by oncologists, surgeons, radiation therapists, and healthcare institutions such as hospitals, oncology clinics, and ambulatory surgical centers. Treatments are administered based on individual patient profiles, prior treatments received, genetic markers, and overall health status. Therapies may be used as standalone interventions or in combination to maximize efficacy and counter resistance.

The global metastatic breast cancer treatment market was valued at $18,572.4 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 5.00%.

Growth Of Precision Medicine And Targeted Therapies

During the historic period, the metastatic breast cancer treatment market was mainly driven by the expansion of precision medicine and targeted therapy approvals. Precision medicine and targeted therapies refer to treatments designed to target specific molecular or genetic features of cancer cells, allowing clinicians to select therapies based on individualized tumor biology rather than using a one size fits all approach. Metastatic breast cancer treatment supported the expansion of precision medicine by incorporating biomarker guided therapy selection into standard clinical practice, enabling more effective disease control and extending survival for patients with specific tumor profiles. For example, in April 2025, according to Karolinska Institute, a medical university located in Sweden, known for its pioneering research and education in biomedical sciences since 1810, the Swedish government allocated a record SEK 80 million (8.56 million USD) to Genomic Medicine Sweden (GMS), marking a substantial increase from the SEK 49.5 million (5.3 million USD) granted in 2024. This investment underscores the growing emphasis on precision medicine and the critical role of AI in advancing these initiatives. Moreover, in 2024, drug approvals include therapies for a variety of diseases and conditions, including rare diseases. FDA approved a significant number of rare disease therapies with orphan drug designation for patients with few to no treatment options. Therapies with orphan drug designations accounted for over 50% of our novel drug approvals, highlighting our steadfast commitment to address the huge unmet medical need in rare diseases. Therefore, the expansion of precision medicine through targeted therapy approvals was driving the growth of the metastatic breast cancer treatment market.

Expansion Of First-Line ADC-Based Targeted Therapy Combinations For HER2-Positive Metastatic Breast Cancer

Major companies operating in the metastatic breast cancer treatment market are focusing on expanding targeted therapy use into earlier lines of treatment, such as first-line antibody-drug conjugate (ADC) combinations that target HER2 with precision. For instance, in December 2025, AstraZeneca, a British-Swedish biopharmaceutical company, and Daiichi Sankyo, a Japan-based pharmaceutical company, introduced the combination of fam-trastuzumab deruxtecan-nxki (Enhertu) with pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast cancer, which uses a validated diagnostic test to select patients and directly delivers cytotoxic agents to HER2-expressing cancer cells to improve progression control. This regulatory approval by the U.S. Food and Drug Administration (FDA) reflects strategic supply-side prioritization of high-efficacy biologics earlier in the care pathway and aligns pricing strategies with value-based care models.

The global metastatic breast cancer treatment market is highly concentrated, with large number of small players operating in the market. The top ten competitors in the market made up to 93.1% of the total market in 2024.

Metastatic Breast Cancer Treatment Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global metastatic breast cancer treatment market as it emerges from the COVID-19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for metastatic breast cancer treatment? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The metastatic breast cancer treatment market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider metastatic breast cancer treatment market; and compares it with other markets.

The report covers the following chapters

• Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by therapy type, by molecule type and by end user.
• Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market
• Growth Analysis And Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
• Global Market Size And Growth Global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
• Regional And Country Analysis- Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
• Market Segmentation- Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by therapy type, by molecule type and by end user in the market. Historic (2020-2025) and forecast (2025-2030) and (2030-2035) market values and growth and market share comparison by region market.
• Regional Market Size and Growth- Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Other Major And Innovative Companies Details on the company profiles of other major and innovative companies in the market.
• Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
• Competitive Dashboard- Briefs on competitive dashboard of major players.
• Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
• Recent Developments Information on recent developments in the market covered in the report.
• Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations- This section includes recommendations for metastatic breast cancer treatment providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
• Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

• 1) By Therapy Type: Chemotherapy; Radiation Therapy; Targeted Therapy; Surgery; Hormone Therapy
• 2) By Molecule Type: Monoclonal Antibody; Peptides And Hormones; Small Molecule; Others
• 3) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users
• Companies Mentioned: F. Hoffmann-La Roche AG (Genentech Inc.); Eli Lilly & Co.; Pfizer Inc.; Novartis AG; Merck & Co. Inc.
• Countries: China; Germany; Japan; UK; France; India; USA; Canada; South Korea; Brazil; Australia; Russia; Spain; Italy; Indonesia
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time-series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; metastatic breast cancer treatment indicators comparison.
• Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

• 1.1 Metastatic Breast Cancer Treatment - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

• 6.1 General Market Definition
• 6.2 Summary
• 6.3 Metastatic Breast Cancer Treatment Market Definition And Segmentations
• 6.4 Market Segmentation By Therapy Type
  • 6.4.1 Chemotherapy
  • 6.4.2 Radiation Therapy
  • 6.4.3 Targeted Therapy
  • 6.4.4 Surgery
  • 6.4.5 Hormone Therapy
• 6.5 Market Segmentation By Molecule Type
  • 6.5.1 Monoclonal Antibody
  • 6.5.2 Peptides And Hormones
  • 6.5.3 Small Molecule
  • 6.5.4 Others
• 6.6 Market Segmentation By End-User
  • 6.6.1 Hospitals
  • 6.6.2 Clinics
  • 6.6.3 Ambulatory Healthcare Centers
  • 6.6.4 Other End-Users

7 Major Market Trends

• 7.1 Expansion Of First-Line ADC-Based Targeted Therapy Combinations For HER2-Positive Metastatic Breast Cancer
• 7.2 Expansion Of Targeted Maintenance Therapy Strategies To Extend Disease Control In HER2-Positive Metastatic Breast Cancer
• 7.3 Development And Commercialization Of Targeted Antibody-Drug Conjugates To Address High-Prevalence Metastatic Breast Cancer Subtypes
• 7.4 Introduction Of Precision Oral Hormone Receptor-Targeted Therapies To Transform Metastatic Breast Cancer Management
• 7.5 Advancement Of Combination Therapy Regimens Targeting Multiple Resistance Pathways In Metastatic Breast Cancer Treatment

8 Global Metastatic Breast Cancer Treatment Growth Analysis And Strategic Analysis Framework

• 8.1 Global Metastatic Breast Cancer Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 8.1.1 Political
  • 8.1.2 Economic
  • 8.1.3 Social
  • 8.1.4 Technological
  • 8.1.5 Environmental
  • 8.1.6 Legal
• 8.2 Analysis of End-User Market(B2B)
  • 8.2.1 Hospitals
  • 8.2.2 Clinics
  • 8.2.3 Ambulatory Healthcare Centers
  • 8.2.4 Other End-Users
• 8.3 Global Metastatic Breast Cancer Treatment Market Growth Rate Analysis
• 8.4 Historic Market Growth, 2020 - 2025, Value ($ Million)
  • 8.4.1 Market Drivers 2020 - 2025
  • 8.4.2 Market Restraints 2020 - 2025
• 8.5 Forecast Market Growth, 2025 - 2030, 2035F Value ($ Million)
• 8.6 Forecast Growth Contributors/Factors
  • 8.6.1 Quantitative Growth Contributors
  • 8.6.2 Drivers
  • 8.6.3 Restraints
• 8.7 Global Metastatic Breast Cancer Treatment Total Addressable Market (TAM)
  • 8.7.1 TAM Comparison Analysis

9 Global Metastatic Breast Cancer Treatment Market Segmentation

• 9.1 Global Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 9.2 Global Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 9.3 Global Metastatic Breast Cancer Treatment Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 9.4 Global Metastatic Breast Cancer Treatment Market, Sub-Segmentation Of Chemotherapy, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 9.5 Global Metastatic Breast Cancer Treatment Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 9.6 Global Metastatic Breast Cancer Treatment Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 9.7 Global Metastatic Breast Cancer Treatment Market, Sub-Segmentation Of Surgery, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 9.8 Global Metastatic Breast Cancer Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

10 Metastatic Breast Cancer Treatment Market, Regional and Country Analysis

• 10.1 Global Metastatic Breast Cancer Treatment Market, By Region, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 10.2 Global Metastatic Breast Cancer Treatment Market, By Country, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

11 Asia-Pacific Market

• 11.1 Summary
• 11.2 Market Overview
  • 11.2.1 Region Information
  • 11.2.2 Market Information
  • 11.2.3 Background Information
  • 11.2.4 Government Initiatives
  • 11.2.5 Regulations
  • 11.2.6 Regulatory Bodies
  • 11.2.7 Major Associations
  • 11.2.8 Taxes Levied
  • 11.2.9 Corporate Tax Structure
  • 11.2.10 Investments
  • 11.2.11 Major Companies
• 11.3 Asia-Pacific Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.4 Asia-Pacific Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.5 Asia-Pacific Metastatic Breast Cancer Treatment Market: Country Analysis
• 11.6 China Market
• 11.7 Summary
• 11.8 Market Overview
  • 11.8.1 Country Information
  • 11.8.2 Market Information
  • 11.8.3 Background Information
  • 11.8.4 Government Initiatives
  • 11.8.5 Regulations
  • 11.8.6 Regulatory Bodies
  • 11.8.7 Major Associations
  • 11.8.8 Taxes Levied
  • 11.8.9 Corporate Tax Structure
  • 11.8.10 Investments
  • 11.8.11 Major Companies
• 11.9 China Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.10 China Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.11 India Market
• 11.12 India Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.13 India Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.14 Japan Market
• 11.15 Summary
• 11.16 Market Overview
  • 11.16.1 Country Information
  • 11.16.2 Market Information
  • 11.16.3 Background Information
  • 11.16.4 Government Initiatives
  • 11.16.5 Regulations
  • 11.16.6 Regulatory Bodies
  • 11.16.7 Major Associations
  • 11.16.8 Taxes Levied
  • 11.16.9 Corporate Tax Structure
  • 11.16.10 Investments
  • 11.16.11 Major Companies
• 11.17 Japan Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.18 Japan Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.19 Australia Market
• 11.20 Australia Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.21 Australia Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.22 Indonesia Market
• 11.23 Indonesia Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.24 Indonesia Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.25 South Korea Market
• 11.26 Summary
• 11.27 Market Overview
  • 11.27.1 Country Information
  • 11.27.2 Market Information
  • 11.27.3 Background Information
  • 11.27.4 Government Initiatives
  • 11.27.5 Regulations
  • 11.27.6 Regulatory Bodies
  • 11.27.7 Major Associations
  • 11.27.8 Taxes Levied
  • 11.27.9 Corporate Tax Structure
  • 11.27.10 Investments
  • 11.27.11 Major Companies
• 11.28 South Korea Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.29 South Korea Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

12 Western Europe Market

• 12.1 Summary
• 12.2 Market Overview
  • 12.2.1 Region Information
  • 12.2.2 Market Information
  • 12.2.3 Background Information
  • 12.2.4 Government Initiatives
  • 12.2.5 Regulations
  • 12.2.6 Regulatory Bodies
  • 12.2.7 Major Associations
  • 12.2.8 Taxes Levied
  • 12.2.9 Corporate tax structure
  • 12.2.10 Investments
  • 12.2.11 Major Companies
• 12.3 Western Europe Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.4 Western Europe Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.5 Western Europe Metastatic Breast Cancer Treatment Market: Country Analysis
• 12.6 UK Market
• 12.7 UK Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.8 UK Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.9 Germany Market
• 12.10 Germany Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.11 Germany Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.12 France Market
• 12.13 France Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.14 France Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.15 Italy Market
• 12.16 Italy Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.17 Italy Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.18 Spain Market
• 12.19 Spain Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.20 Spain Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

13 Eastern Europe Market

• 13.1 Summary
• 13.2 Market Overview
  • 13.2.1 Region Information
  • 13.2.2 Market Information
  • 13.2.3 Background Information
  • 13.2.4 Government Initiatives
  • 13.2.5 Regulations
  • 13.2.6 Regulatory Bodies
  • 13.2.7 Major Associations
  • 13.2.8 Taxes Levied
  • 13.2.9 Corporate Tax Structure
  • 13.2.10 Major Companies
• 13.3 Eastern Europe Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 13.4 Eastern Europe Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 13.5 Eastern Europe Metastatic Breast Cancer Treatment Market: Country Analysis
• 13.6 Russia Market
• 13.7 Russia Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 13.8 Russia Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

14 North America Market

• 14.1 Summary
• 14.2 Market Overview
  • 14.2.1 Region Information
  • 14.2.2 Market Information
  • 14.2.3 Background Information
  • 14.2.4 Government Initiatives
  • 14.2.5 Regulations
  • 14.2.6 Regulatory Bodies
  • 14.2.7 Major Associations
  • 14.2.8 Taxes Levied
  • 14.2.9 Corporate Tax Structure
  • 14.2.10 Investments
  • 14.2.11 Major Companies
• 14.3 North America Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 14.4 North America Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 14.5 North America Metastatic Breast Cancer Treatment Market: Country Analysis
• 14.6 USA Market
• 14.7 Summary
• 14.8 Market Overview
  • 14.8.1 Country Information
  • 14.8.2 Market Information
  • 14.8.3 Background Information
  • 14.8.4 Government Initiatives
  • 14.8.5 Regulations
  • 14.8.6 Regulatory Bodies
  • 14.8.7 Major Associations
  • 14.8.8 Taxes Levied
  • 14.8.9 Corporate Tax Structure
  • 14.8.10 Investments
  • 14.8.11 Major Companies
• 14.9 USA Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 14.10 USA Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 14.11 Canada Market
• 14.12 Summary
• 14.13 Market Overview
  • 14.13.1 Country Information
  • 14.13.2 Market Information
  • 14.13.3 Background Information
  • 14.13.4 Government Initiatives
  • 14.13.5 Regulations
  • 14.13.6 Regulatory Bodies
  • 14.13.7 Major Associations
  • 14.13.8 Taxes Levied
  • 14.13.9 Corporate Tax Structure
  • 14.13.10 Investments
  • 14.13.11 Major Companies
• 14.14 Canada Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 14.15 Canada Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

15 South America Market

• 15.1 Summary
• 15.2 Market Overview
  • 15.2.1 Region Information
  • 15.2.2 Market Information
  • 15.2.3 Background Information
  • 15.2.4 Government Initiatives
  • 15.2.5 Regulations
  • 15.2.6 Regulatory Bodies
  • 15.2.7 Major Associations
  • 15.2.8 Taxes Levied
  • 15.2.9 Corporate Tax Structure
  • 15.2.10 Major Companies
• 15.3 South America Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 15.4 South America Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 15.5 South America Metastatic Breast Cancer Treatment Market: Country Analysis
• 15.6 Brazil Market
• 15.7 Brazil Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 15.8 Brazil Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

16 Middle East Market

• 16.1 Summary
• 16.2 Market Overview
  • 16.2.1 Region Information
  • 16.2.2 Market Information
  • 16.2.3 Background Information
  • 16.2.4 Government Initiatives
  • 16.2.5 Regulations
  • 16.2.6 Regulatory Bodies
  • 16.2.7 Major Associations
  • 16.2.8 Taxes Levied
  • 16.2.9 Corporate Tax Structure
  • 16.2.10 Major Companies
• 16.3 Middle East Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 16.4 Middle East Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

17 Africa Market

• 17.1 Summary
• 17.2 Market Overview
  • 17.2.1 Region Information
  • 17.2.2 Market Information
  • 17.2.3 Background Information
  • 17.2.4 Government Initiatives
  • 17.2.5 Regulations
  • 17.2.6 Regulatory Bodies
  • 17.2.7 Major Associations
  • 17.2.8 Taxes Levied
  • 17.2.9 Corporate Tax Structure
  • 17.2.10 Major Companies
• 17.3 Africa Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.4 Africa Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

18 Competitive Landscape And Company Profiles

• 18.1 Company Profiles
• 18.2 F. Hoffmann-La Roche AG (Genentech Inc.)
  • 18.2.1 Company Overview
  • 18.2.2 Products And Services
  • 18.2.3 Business Strategy
  • 18.2.4 Financial Overview
• 18.3 Eli Lilly & Co.
  • 18.3.1 Company Overview
  • 18.3.2 Products And Services
  • 18.3.3 Business Strategy
  • 18.3.4 Financial Overview
• 18.4 Pfizer Inc.
  • 18.4.1 Company Overview
  • 18.4.2 Products And Services
  • 18.4.3 Financial Overview
• 18.5 Novartis AG
  • 18.5.1 Company Overview
  • 18.5.2 Products And Services
  • 18.5.3 Financial Overview
• 18.6 Merck & Co. Inc.
  • 18.6.1 Company Overview
  • 18.6.2 Products And Services
  • 18.6.3 Financial Overview

19 Other Major And Innovative Companies

• 19.1 Gilead Sciences Inc.
  • 19.1.1 Company Overview
  • 19.1.2 Products And Services
• 19.2 AstraZeneca plc.
  • 19.2.1 Company Overview
  • 19.2.2 Products And Services
• 19.3 Bristol-Myers Squibb Company
  • 19.3.1 Company Overview
  • 19.3.2 Products And Services
• 19.4 Amgen Inc.
  • 19.4.1 Company Overview
  • 19.4.2 Products And Services
• 19.5 Mayo Clinic
  • 19.5.1 Company Overview
  • 19.5.2 Products And Services
• 19.6 Johns Hopkins Hospital
  • 19.6.1 Company Overview
  • 19.6.2 Products And Services
• 19.7 Stanford Health Care
  • 19.7.1 Company Overview
  • 19.7.2 Products And Services
• 19.8 Dana-Farber Cancer Institute
  • 19.8.1 Company Overview
  • 19.8.2 Products And Services
• 19.9 University of Texas MD Anderson Cancer Center
  • 19.9.1 Company Overview
  • 19.9.2 Products And Services
• 19.10 Hannover Medical School
  • 19.10.1 Company Overview
  • 19.10.2 Products And Services
• 19.11 Eisai Co. ltd.
  • 19.11.1 Company Overview
  • 19.11.2 Products And Services
• 19.12 Samsung Medical Center
  • 19.12.1 Company Overview
  • 19.12.2 Products And Services
• 19.13 MacroGenics Inc.
  • 19.13.1 Company Overview
  • 19.13.2 Products And Services
• 19.14 RemeGen Co. Ltd.
  • 19.14.1 Company Overview
  • 19.14.2 Products And Services
• 19.15 Abraxis Bioscience LLC.
  • 19.15.1 Company Overview
  • 19.15.2 Products And Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

• 22.1 Athira Pharma Acquired Lasofoxifene Rights From Sermonix Pharmaceuticals

23 Recent Developments In Metastatic Breast Cancer Treatment

• 23.1 FDA Approval Of Imlunestrant For ESR1-Mutated Metastatic Breast Cancer

24 Opportunities And Strategies

• 24.1 Global Metastatic Breast Cancer Treatment Market In 2030 - Countries Offering Most New Opportunities
• 24.2 Global Metastatic Breast Cancer Treatment Market In 2030 - Segments Offering Most New Opportunities
• 24.3 Global Metastatic Breast Cancer Treatment Market In 2030 - Growth Strategies
  • 24.3.1 Market Trend Based Strategies
  • 24.3.2 Competitor Strategies

25 Metastatic Breast Cancer Treatment Market, Conclusions And Recommendations

• 25.1 Conclusions
• 25.2 Recommendations
  • 25.2.1 Product
  • 25.2.2 Place
  • 25.2.3 Price
  • 25.2.4 Promotion
  • 25.2.5 People

26 Appendix

• 26.1 Geographies Covered
• 26.2 Market Data Sources
• 26.3 Research Methodology
• 26.4 Currencies
• 26.5 The Business Research Company
• 26.6 Copyright and Disclaimer